Internal Medicine, Rheumatology · South Miami, FL
NPI
1124229091
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
6280 Sunset Dr Ste 501
South Miami, FL, 33143
Phone (305) 671-3447
Groups this clinician bills Medicare through
Medicare paid, 2024
$595K
44,316 services
Medicare patients, 2024
142
Average age 73
Drug cost, 2024
$1.9M
477 prescriptions
Company payments, 2025
$7,751
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Olga Kromo was code J0129 (injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 6,225 times for 27 patients. In total Olga Kromo billed 44,316 services in 52 codes, and Medicare paid $595K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 6,225 | 27 | $22.31 | $139K |
| J0897 Injection, denosumab, 1 mg | Office | 2,401 | 41 | $15.34 | $37K |
| 96401 Chemotherapy Administration | Office | 175 | 54 | $57.37 | $10K |
| 96413 Chemotherapy Administration | Office | 132 | 44 | $103.34 | $14K |
| J7324 Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | Office | 109 | 16 | $95.89 | $10K |
| 20610 Joint Injection | Office | 77 | 23 | $79.39 | $6,113 |
| 36415 Venipuncture Blood Collection | Office | 62 | 43 | $8.52 | $528 |
| 96372 Injection Administration | Office | 40 | 22 | $11.82 | $473 |
| 99215 Office E&M - Established | Office | 33 | 22 | $138.07 | $4,556 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 31 | 15 | $0.99 | $30.8 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 24 | 19 | $14.08 | $338 |
| 99214 Office E&M - Established | Office | 20 | 19 | $110.00 | $2,200 |
| 72040 X-ray - Spine and Pelvis | Office | 18 | 18 | $27.21 | $490 |
| 72070 X-ray - Spine and Pelvis | Office | 18 | 18 | $22.34 | $402 |
| 72100 X-ray - Spine and Pelvis | Office | 18 | 18 | $25.84 | $465 |
By year: 2022 $857K for 78,044 services; 2023 $781K for 75,798 services; 2024 $595K for 44,316 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 62 | 43 | $8.52 | $528 |
Medicare prescription drug claims, 2024
In 2024, the drug Olga Kromo prescribed most often to Medicare patients was Prolia (Denosumab), with 110 prescriptions and refills. In total Olga Kromo wrote 477 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prolia Denosumab | 110 | 660 | 72 | $193K |
| Orencia Abatacept/Maltose | 79 | 79 | 14 | $367K |
| Cosentyx Sensoready (2 Pens) Secukinumab | 53 | 53 | Under 11 | $389K |
| Simponi Aria Golimumab | 39 | 56 | 12 | $270K |
| Tramadol Hcl Generic | 37 | 37 | Under 11 | $427 |
| Actemra Tocilizumab | 20 | 20 | Under 11 | $67K |
| Evenity (2 Syringes) Romosozumab-Aqqg | 20 | 20 | Under 11 | $50K |
| Cimzia (2 Pack) Certolizumab Pegol | 18 | 18 | Under 11 | $103K |
| Taltz Autoinjector Ixekizumab | 17 | 17 | Under 11 | $114K |
Brand drugs: 385 claims; generic drugs: 92 claims; opioid claims: 45.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Olga Kromo $7,751 ($7,751 in general payments such as food, travel and fees) from 30 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $1,230.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 17 | $1,230 |
| Janssen Research & Development, LLC JNJ | 10 | $1,173 |
| AstraZeneca UK Limited AZN | 6 | $748 |
| Amgen Inc. AMGN | 35 | $683 |
| UCB, Inc. UCB.BR | 28 | $587 |
| Abbvie Inc. ABBV | 31 | $586 |
| Janssen Biotech, Inc. JNJ | 28 | $513 |
| Novartis Pharmaceuticals Corporation NVS | 25 | $437 |
| GlaxoSmithKline, LLC. GSK | 13 | $255 |
| Mallinckrodt Hospital Products Inc. | 20 | $251 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.